Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1

Mishin, Vasiliy P.; Patel, Manan S.; Chesnokov, Anton; Cruz, Juan de la; Nguyen, Ha; Lollis, Lori; Hodges, Erin; Jang, Yunho; Barnes, John; Uyeki, Timothy M.; Davis, C. Todd; Wentworth, David E.; Gubareva, Larisa V.

doi:10.3201/eid2510.190607

Cited by 58 publications

(33 citation statements)

References 15 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RNA and DNA polymerases . Favipiravir inhibits the replication of influenza A, B, C, and D viruses, including matrix protein 2 (M2) inhibitor-resistant viruses and neuraminidase (NA) inhibitor-resistant viruses (Furuta et al 2002;Mishin et al 2019).…”

Section: Antiviral Activitymentioning

confidence: 99%

See 1 more Smart Citation

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Takashita

2020

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Section: Antiviral Activitymentioning

confidence: 99%

“…Baloxavir has activity against influenza A, B, C, and D viruses, including NA inhibitor-resistant viruses Mishin et al 2019). Influenza B viruses are less susceptible to baloxavir than are influenza A viruses Koszalka et al 2019); the susceptibility pattern is influenza A>B>C>D .…”

Section: Influenza Polymerase Inhibitorsmentioning

confidence: 99%

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Takashita

2020

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

“…[73][74][75] In addition to activity against IAVs, IBVs and influenza viruses of the C and D genera are susceptible to baloxavir inhibition, making the drug a truly broad-spectrum influenza virus inhibitor. 71,76,77 Baloxavir marboxil was well tolerated in clinical trials with only mild and transient adverse events that resolved without further intervention. Side effects included headaches and increased eosinophil and white blood cell counts.…”

Section: Clinically Used Drugs and Selected Daa Candidates In Advancementioning

confidence: 99%

Next-generation direct-acting influenza therapeutics

Toots

Plemper

2020

Translational Research

View full text Add to dashboard Cite

Influenza viruses are a major threat to human health globally. In addition to further improving vaccine prophylaxis, disease management through antiviral therapeutics constitutes an important component of the current intervention strategy to prevent advance to complicated disease and reduce case-fatality rates. Standard-of-care is treatment with neuraminidase inhibitors that prevent viral dissemination. In 2018, the first mechanistically new influenza drug class for the treatment of uncomplicated seasonal influenza in 2 decades was approved for human use. Targeting the PA endonuclease subunit of the viral polymerase complex, this class suppresses viral replication. However, the genetic barrier against viral resistance to both drug classes is low, pre-existing resistance is observed in circulating strains, and resistant viruses are pathogenic and transmit efficiently. Addressing the resistance problem has emerged as an important objective for the development of next-generation influenza virus therapeutics. This review will discuss the status of influenza therapeutics including the endonuclease inhibitor baloxavir marboxil after its first year of clinical use and evaluate a subset of direct-acting antiviral candidates in different stages of preclinical and clinical development.

show abstract

“…This oral antiviral inhibits viral replication by targeting the endonuclease function encoded by the polymerase acidic subunit of the viral polymerase. It has shown broad antiviral activity against all known types of Influenza (A, B, C and D) and the Influenza A viruses of avian and swine origin which have the potential to cause pandemic [22].…”

Section: Treatmentmentioning

confidence: 99%

Influenza

Dharmapalan

2020

Indian J Pediatr

View full text Add to dashboard Cite

Influenza continues to baffle humans by its constantly changing nature. The twenty-first century has witnessed considerable advances in the understanding of the influenza viral pathogenesis, its synergy with bacterial infections and diagnostic methods. However, challenges continue: to find a less expensive and more reliable point-of-care test for use in developing countries, to produce more efficacious antiviral drugs, to explore ways to combat emerging antiviral resistance and to develop vaccines that can either be produced in a shorter production time or can overcome the need for annual matching with the circulating influenza strains. Most importantly for India, as a nation that suffered the highest mortality in the influenza pandemic 1918, there is an urgent need to gear up our existing preparedness for the next pandemic which is capable to hit at any moment in time.

show abstract

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1

Cited by 58 publications

References 15 publications

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Next-generation direct-acting influenza therapeutics

Influenza

Contact Info

Product

Resources

About